Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an announcement.
BioArctic AB has received a positive opinion from the European Medicines Agency for orphan medicinal product designation for exidavnemab, a treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease. This designation provides incentives for developing treatments for rare diseases, potentially enhancing BioArctic’s market positioning and offering hope for addressing high unmet medical needs in MSA and related disorders.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases. They are known for originating Leqembi®, a drug that slows the progression of Alzheimer’s disease. The company has a broad research portfolio that includes Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, utilizing proprietary technology to improve drug transport into the brain. BioArctic’s B share is listed on Nasdaq Stockholm Large Cap.
Average Trading Volume: 290,954
Current Market Cap: SEK16.38B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.